News

08/10/23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised for Phase 2 Trial Initiation Later in 2H23 Company Completes $5 million Equity Raise, Extending Cash Runway into 3Q24 SEATTLE, WA / ACCESSWIRE / August 10, 2023 /
08/04/23
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of its previously announced public offering of 2,221,550
08/01/23
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 1, 2023 /   Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced that the Company has entered into definitive agreements with
07/18/23
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEATTLE, WA / ACCESSWIRE / July 18, 2023 /   Aptevo Therapeutics
05/11/23
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor and T Cell Stimulator SEATTLE, WA / ACCESSWIRE / May 11, 2023 /
03/30/23
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on
03/30/23
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA / ACCESSWIRE / March 30, 2023 /   Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology
02/13/23
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of
01/09/23
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline SEATTLE, WA / ACCESSWIRE / January 9, 2023   /   Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology